- Home
- DTSS vs BLRX Comparison
DTSS vs BLRX Comparison
Compare DTSS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- BLRX
- Stock Information
- Founded
- DTSS 2014
- BLRX 2003
- Country
- DTSS China
- BLRX Israel
- Employees
- DTSS N/A
- BLRX N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- BLRX Health Care
- Exchange
- DTSS Nasdaq
- BLRX Nasdaq
- Market Cap
- DTSS 14.2M
- BLRX 17.3M
- IPO Year
- DTSS N/A
- BLRX 2011
- Fundamental
- Price
- DTSS $2.09
- BLRX $3.59
- Analyst Decision
- DTSS
- BLRX Strong Buy
- Analyst Count
- DTSS 0
- BLRX 2
- Target Price
- DTSS N/A
- BLRX $5.50
- AVG Volume (30 Days)
- DTSS 282.3K
- BLRX 432.3K
- Earning Date
- DTSS 02-11-2025
- BLRX 03-25-2025
- Dividend Yield
- DTSS N/A
- BLRX N/A
- EPS Growth
- DTSS N/A
- BLRX N/A
- EPS
- DTSS N/A
- BLRX N/A
- Revenue
- DTSS $38,176,218.00
- BLRX $21,991,000.00
- Revenue This Year
- DTSS N/A
- BLRX N/A
- Revenue Next Year
- DTSS N/A
- BLRX N/A
- P/E Ratio
- DTSS N/A
- BLRX N/A
- Revenue Growth
- DTSS 262.84
- BLRX N/A
- 52 Week Low
- DTSS $1.47
- BLRX $0.08
- 52 Week High
- DTSS $20.29
- BLRX $4.44
- Technical
- Relative Strength Index (RSI)
- DTSS 43.70
- BLRX 92.08
- Support Level
- DTSS $1.82
- BLRX $3.24
- Resistance Level
- DTSS $2.06
- BLRX $3.70
- Average True Range (ATR)
- DTSS 0.24
- BLRX 0.17
- MACD
- DTSS -0.01
- BLRX 0.41
- Stochastic Oscillator
- DTSS 17.19
- BLRX 77.98
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.